Analyst Ratings for Madrigal Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Madrigal Pharmaceuticals (NASDAQ:MDGL) received 6 analyst ratings in the last quarter with an average price target of $249.67, representing an upside from the current price of $139.66. The new average price target is a 9.21% decrease from the previous target of $275.00. Ratings included 3 bullish, 1 somewhat bullish, and 2 indifferent, with no bearish or somewhat bearish ratings.
November 13, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals has a positive outlook from analysts with an average price target of $249.67, suggesting a significant upside from the current price. The recent decrease in the target may temper expectations slightly.
The average price target suggests that analysts believe the stock has a strong upside potential, which is typically a positive signal for investors. However, the decrease in the target price could indicate some caution, possibly due to new market information or revised earnings projections. The lack of bearish ratings adds to the positive sentiment, but as analyst ratings are not guarantees of performance, the score reflects cautious optimism.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100